The past and future of genetics in pulmonary disease: You can teach an old dog new tricks.
The past and future of genetics in pulmonary disease: You can teach an old dog new tricks.
复制标题
肺部疾病遗传学的过去和未来:你可以教老狗新把戏。
DOI:
10.1002/ppul.24669
复制
发表时间:
2020
影响因子:
3.1
通讯作者:
Hamvas,Aaron
中科院分区:
文献类型:
--
作者:
Nogee,LawrenceM;Hamvas,Aaron
Pediatric Pulmonologists have long incorporated advances in genetics into their every-day practice through their care of children with cystic fibrosis (CF). First described in 1938 by Dorothy Anderson, the genetic basis and recessive inheritance pattern of CF was recognized early on. The identification of a reliable biomarker–sweat chloride-allowed for establishing the diagnosis, even in the absence of the known genetic defect, and the sweat test remains an essential component of CF diagnosis today. The identification of the CF gene in 1989 was a landmark achievement–accomplished through positional mapping and sequencing using methods that have since been supplanted by faster and more cost-effective approaches. The identification of the basic defect in CF, an understanding of the biology of the mutated protein, and development of in vitro tools to study mutated proteins has now led to the development of drugs to rescue CFTR function that are likely to transform the nature of CF treatment.The Human Genome Project and the subsequent rapid expansion of genomic technology has provided deeper understanding of underlying mechanisms of disease and enhanced the approaches to diagnosis for both recognized and unknown disorders. Thus, pediatric pulmonologists are now increasingly faced with new genetic disorders, or the ability to noninvasively diagnoses disorders that were previously defined largely by their associated lung histopathology and required lung biopsies for diagnosis. As an example, genetic disorders of surfactant metabolism result in a spectrum of disease from neonatal respiratory failure to adult onset pulmonary fibrosis (1-7). The lung histopathology diagnoses associated with surfactant dysfunction disorders is variable, and includes diagnoses referred to as pulmonary alveolar proteinosis, desquamative interstitial pneumonia, chronic pneumonitis of infancy, non-specific interstitial pneumonia, and usual interstitial pneumonia. The surfactant disorders highlight two important points: 1) pathogenic variants in different genes may manifest with a similar clinical or histopathologic phenotype; and 2) mutations in the same gene may manifest with variable phenotypic expression, even within families, also suggesting that genetic background and environmental exposures play a role in the expression of phenotype. These observations raise fundamental questions concerning how to define disease, whether based on clinical, imaging, or lung histopathology or the underlying mechanism–a conundrum that will occur more often as new genetic mechanisms for childhood lung disease are uncovered.
登录
查看更多内容
影响因子:
6.2
作者:
Tarter,RE;Switala,JA;Arria,A;Plail,J;VanThiel,DH
通讯作者:
VanThiel,DH
影响因子:
--
作者:
Brandt,J;Butters,N;Ryan,C;Bayog,R
通讯作者:
Bayog,R
DOI:
--
发表时间:
1983
期刊:
影响因子:
--
作者:
J. Saunders;Roger Williams
通讯作者:
Roger Williams
影响因子:
1.9
作者:
ALLEN, RP;WAGMAN, A;MCINTOSH, M
通讯作者:
MCINTOSH, M
DOI:
--
发表时间:
1957
期刊:
The Lancet
影响因子:
--
作者:
B. Parsons;W. Summerskill;A. Dawson;S. Sherlock
通讯作者:
S. Sherlock